Search Results - Guiling Li
- Showing 1 - 2 results of 2
-
1
-
2
Multicenter phase 1/2 study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in advanced solid tumors by Pei Shu, Xiaoyu Li, Qi Zhou, Guiling Li, Keqiang Zhang, Li Yuan, Yixian Liu, Qiu Li, Yongsheng Wang, Hui Xie, Li Zheng
Published 2025-06-01
Article